Sivia Capital Partners LLC Has $387,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Sivia Capital Partners LLC grew its holdings in Danaher Co. (NYSE:DHR) by 34.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,890 shares of the conglomerate’s stock after purchasing an additional 480 shares during the quarter. Sivia Capital Partners LLC’s holdings in Danaher were worth $387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Spinnaker Trust raised its position in Danaher by 1.2% during the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock valued at $988,000 after purchasing an additional 50 shares in the last quarter. Fortis Capital Advisors LLC lifted its stake in shares of Danaher by 1.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate’s stock valued at $914,000 after acquiring an additional 50 shares during the last quarter. Fayez Sarofim & Co lifted its stake in shares of Danaher by 0.6% in the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock valued at $1,902,000 after acquiring an additional 50 shares during the last quarter. Coastal Bridge Advisors LLC lifted its stake in shares of Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock valued at $252,000 after acquiring an additional 50 shares during the last quarter. Finally, Perennial Investment Advisors LLC lifted its stake in shares of Danaher by 2.2% in the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 51 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 2.1%

DHR stock opened at $196.13 on Friday. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The business’s 50 day moving average price is $191.34 and its two-hundred day moving average price is $212.19. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company has a market capitalization of $140.36 billion, a price-to-earnings ratio of 37.15, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. As a group, analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher’s dividend payout ratio (DPR) is 24.85%.

Insiders Place Their Bets

In other news, EVP Christopher Paul Riley sold 15,805 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares of the company’s stock, valued at $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on DHR shares. HSBC lowered their target price on Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Sunday, June 1st. Jefferies Financial Group lowered their target price on Danaher from $260.00 to $230.00 and set a “buy” rating for the company in a research note on Tuesday, April 22nd. Robert W. Baird lowered their target price on Danaher from $231.00 to $225.00 and set an “outperform” rating for the company in a research note on Wednesday, April 23rd. Finally, Stifel Nicolaus raised Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price for the company in a research note on Friday, March 14th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $263.24.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.